SRI-37330|cas:2322245-42-9|西域试剂

SRI-37330,98.76%

产品编号：Bellancom-142114| CAS NO：2322245-42-9| 分子式：C₁₆H₁₉F₃N₄O₂S| 分子量：388.41

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-142114	￥1350.00	杭州北京（现货）
Bellancom-142114	￥2250.00	杭州北京（现货）
Bellancom-142114	￥4950.00	杭州北京（现货）
Bellancom-142114	￥8550.00	杭州北京（现货）
Bellancom-142114	￥13950.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SRI-37330

产品介绍

SRI-37330 是一种具有口服活性的 TXNIP 抑制剂。SRI-37330 降低胰高血糖素的分泌和作用，并阻断肝脏葡萄糖输出。SRI-37330 可用于肥胖和糖尿病的研究。

生物活性

SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes.

体外研究

SRI-37330 (1 μM, 24 h) inhibits the activity of the human TXNIP promoter in INS-1 cells.
SRI-37330 (1 μM, 24 h) inhibits Mrna and protein levels of TXNIP in INS-1 cells.
SRI-37330 (5 μM, 24 h) inhibits polymerase II (Pol II) binding to the E-box motif region of the TXNIP promoter.
SRI-37330 (5 μM, 24 h) lowers glucagon secretion in TC1-6 cells.
SRI-37330 (0-5 μM, 24 h) inhibits glucagon-induced glucose output from primary hepatocytes.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line:	INS-1 cells
Concentration:	1 μM
Incubation Time:	24 h
Result:	Inhibited endogenous TXNIP mRNA expression with an IC₅₀ of 0.64 μM.

体内研究
(In Vivo)

SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) decreases glucagon secretion and action and blocks hepatic glucose output.
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice.
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice
Dosage:	100 mg/kg
Administration:	Oral administration (p.o.), in drinking water, 3 weeks.
Result:	Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice
Dosage:	100 mg/kg
Administration:	Oral administration (p.o.), in drinking water, 3 weeks.
Result:	Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice
Dosage:	100 mg/kg
Administration:	Oral administration (p.o.), in drinking water, 3 weeks.
Result:	Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (257.46 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5746 mL	12.8730 mL	25.7460 mL
5 mM	0.5149 mL	2.5746 mL	5.1492 mL
10 mM	0.2575 mL	1.2873 mL	2.5746 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

参考文献